Evidence map›Paper›PMID 39758245›Full record

ArticleCancer diagnosis & prognosis

Outcomes of Combined Atezolizumab Plus Chemotherapy in Non-small Cell Lung Cancer Patients in Clinical Practice.

Takeshi Numata, Ryota Nakamura, Toshihiro Shiozawa, Hiroko Watanabe, Shinichiro Okauchi, Gen Ogara, Tomohiro Tamura, Norihiro Kikuchi, Kunihiko Miyazaki, Shigen Hayashi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takeshi NumataDepartments of Respiratory Medicine and Surgery, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan.
Ryota NakamuraDepartments of Respiratory Medicine and Surgery, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan.
Toshihiro ShiozawaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroko WatanabeDivision of Respiratory Medicine, Tsukuba Memorial Hospital, Tsukuba, Japan.
Shinichiro OkauchiDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Gen OgaraDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Tomohiro TamuraRespiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Norihiro KikuchiDivision of Respiratory Medicine, National Hospital Organization Kasumigaura Medical Center, Tsuchiura, Japan.
Kunihiko MiyazakiDivision of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Shigen HayashiDivision of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan.
Takaaki YamashitaDivision of Respiratory Medicine, JA Toride Medical Center Hospital, Toride, Japan.
Koichi KurishimaDivision of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Japan.
Masaharu InagakiDivision of Thoracic Surgery, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan.
Hiroaki SatohDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Takayuki KaburagiRespiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Takeo EndoDepartments of Respiratory Medicine and Surgery, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Atezolizumab, one of the anti-PD-L1 antibodies, targets PD-L1 expressed on cancer cells and antigen-presenting cells. This immune checkpoint inhibitor is now commonly used in combination with chemotherapy. The objectives of this study were to confirm the treatment outcomes of combined atezolizumab plus chemotherapy, and to identify prognostic factors, with a particular focus on the impact of the site of metastasis in real-world clinical practice. Patients and Methods: A retrospective review of clinical information on non-small cell lung cancer patients who received combined atezolizumab plus chemotherapy from May 2018 to August 2024 at our 11 hospitals was conducted. Results: The 141 patients evaluated had a median progression-free survival of 8.0 months and a median overall survival of 19.0 months. Multivariate analyses showed that 'absence of liver metastases', 'absence of adrenal metastases', 'first-line combined atezolizumab plus chemotherapy', and 'good performance status' were associated with progression-free survival and overall survival. Immune-related adverse events were observed in 27.7% of patients, with grade 3 or higher in 9.9% of patients, and grade 5 in 2.1% of patients. Conclusion: Efficacy and immune-related adverse events associated with the combination of atezolizumab and chemotherapy in non-small cell lung cancer patients were comparable to previous clinical trials. To ensure that appropriate patients receive the most effective treatment, it is important to identify detailed prognostic factors, including clinical information, such as the affected metastatic organs. Continued research and further accumulation of knowledge in this area are eagerly anticipated.

Indexed as

Atezolizumabchemotherapyclinical practicenon-small cell lung cancer

Identifiers

PMID39758245
PMCPMC11696331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.